Central banks are still wrestling with inflation risks, and higher long term yields are keeping pressure on weaker balance sheets. That puts a premium on companies that are not only growing earnings, but also have the financial strength to handle a bumpier rate path. This Healthy high growth potential screener filters for exactly that. Ahead are three stocks from the list that show how this mix of growth and resilience can look in practice.

The stocks below are just a small sample from this idea. The full screen surfaced 283 more companies with equally compelling stories that are not covered here. If you want to go straight to the source and identify your own high conviction candidates, head into the Healthy high growth potential screener.

Amylyx Pharmaceuticals (AMLX)

Overview: Amylyx Pharmaceuticals is a US based clinical stage company developing drug candidates for neurodegenerative diseases and rare endocrine conditions, with AMX0114 for ALS and AMX0035 for conditions such as progressive supranuclear palsy at the center of its growth story. These late and mid stage neurology programs, alongside avexitide for post bariatric hypoglycemia, are the main reason Amylyx appears in the Healthy high growth potential screener.

Market Cap: $4.3b

Amylyx Pharmaceuticals may be of interest if you are looking for a higher risk growth story backed by tangible clinical programs rather than legacy sales. Positive Phase 3 LUCIDITY data for avexitide in post bariatric hypoglycemia and plans to submit an NDA by the end of 2026 show a defined path toward a potential first commercial product. AMX0114 and AMX0035 provide additional longer term earnings potential that is tied to neurological diseases with significant unmet need. The company currently reports losses, depends on external funding and equity raises, and is heavily exposed to the outcomes of regulatory reviews and future market uptake. For investors who are comfortable with clinical and dilution risk, the combination of a developing GLP 1 antagonist franchise and a neurology pipeline makes Amylyx a company that may warrant closer examination.

Amylyx Pharmaceuticals has an accelerating story in neuro and endocrine disorders, yet the real swing factors sit beneath the headlines. Get the full picture with the 2 key rewards and 4 important warning signs (2 are major!)

Oracle (ORCL)

Overview: Oracle is a global enterprise software company that helps businesses run critical operations in the cloud through its Fusion Cloud applications, NetSuite suite, and Oracle Cloud Infrastructure, while still generating sizeable revenue from traditional software licenses and hardware. For the Healthy high growth potential theme, the key interest is Oracle’s fast growing cloud and AI platform, which is backed by a very large multi year contract backlog for AI and database workloads.

Operations: Oracle generates most of its revenue from Cloud and software at about US$58.5b, with smaller contributions from Services at about US$5.7b and Hardware at about US$3.1b.

Market Cap: US$410.3b

Oracle provides exposure to a large scale cloud and AI platform, where Fusion Cloud, NetSuite and Oracle Cloud Infrastructure are driving forecasts for revenue and earnings growth of around 24% a year over the next three years. The company reports high profitability and return on equity, helped by rich software margins and a large AI and cloud contract backlog that supports long term growth expectations. At the same time, high debt levels, negative free cash flow during heavy data center build outs, and a dividend that is not well covered by cash flows mean funding risk is real and worth tracking closely. For investors who want growth but care about financial strength, Oracle is a complex story that may warrant deeper research beyond the headline AI narrative.

Oracle’s cloud and AI story is accelerating, yet the real question is how durable those revenue and earnings forecasts really are. Get the analyst forecasts for Oracle and see what the numbers might be hinting at next.

Iovance Biotherapeutics (IOVA)

Overview: Iovance Biotherapeutics is a commercial stage biotech company focused on autologous tumor infiltrating lymphocyte cell therapies, led by Amtagvi for advanced melanoma and a late stage pipeline that targets multiple solid tumors. This TIL platform, including lifileucel and next generation programs, is the main reason Iovance fits the Healthy high growth potential theme, because it concentrates the business on therapies that are designed to support strong revenue and earnings growth while staying within an acceptable financial framework.

Operations: Iovance Biotherapeutics currently generates about US$325 million in revenue from developing and commercializing autologous TIL based therapies, with roughly US$321 million from the United States and about US$4 million from the rest of the world.

Market Cap: US$3.7b

For investors focused on the Healthy high growth potential theme, Iovance Biotherapeutics offers a direct link between expected high earnings growth and a clear commercial engine in Amtagvi, supported by a broader TIL pipeline that targets several difficult cancers. Forecasts for revenue and earnings growth over the next 3 years are strong, helped by recent quarters, an expanding network of authorized treatment centers and ongoing regulatory progress. At the same time the company still reports losses, relies heavily on external funding and has shown past dilution and share price volatility, so risk tolerance needs to be higher. If you want a closer look at how that balance of TIL revenues and funding risk stacks up over time, there is more to unpack in the full story.

Iovance Biotherapeutics has an accelerating TIL revenue story that many investors may be underestimating, yet the real twist sits in how the analyst forecasts for Iovance Biotherapeutics line up against its funding risks and recent volatility

Seeking Alternatives Before The Crowd Moves

Fresh ideas move first, and the strongest stories often break out while most investors are still watching. Use these curated lists before the momentum gets fully caught, and consider acting early if they fit your process.

• Target resilient compounders with reliable balance sheets by scanning the list of solid balance sheet and fundamentals (51 results) that prioritises financial strength while this group is still largely under the radar.
• Explore structural demand in power infrastructure by reviewing the 38 power grid technology and infrastructure stocks focused on companies supporting grid upgrades.
• Identify early leaders in full stack AI build outs by using the 55 AI infrastructure stocks curated for businesses supplying the hardware and services behind rising AI workloads.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.